StreetInsider.com News Articles

Form 6-K Nyxoah SA For: Oct 20

Tue, 20 Oct 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20261020/27210629.html

Nyxoah Announces Preliminary Results for the Third Quarter of 2026 and Adjusts Revenue Guidance for 2026

Mon, 19 Oct 2026 08:00:00 -0400

REGULATED INFORMATION
INSIDE INFORMATION

Nyxoah Announces Preliminary Results for the Third Quarter of 2026 and Adjusts Revenue Guidance for 2026

U.S. net revenue grows 29% sequentially, driving third quarter global preliminary net revenue of €9.2 million
PMA supplement submitted to the FDA to expand Genio’s U.S. indication to Complete Concentric Collapse patients

Mont-Saint-Guibert, Belgium – October 19, 2026, 2:00 pm CET / 08:00 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported

Nyxoah Announces Preliminary Results for the Third Quarter of 2026 and Adjusts Revenue Guidance for 2026

Mon, 19 Oct 2026 08:00:00 -0400

REGULATED INFORMATION
INSIDE INFORMATION

Nyxoah Announces Preliminary Results for the Third Quarter of 2026 and Adjusts Revenue Guidance for 2026

Nyxoah reports 12-month ACCCESS study data at ISSS meeting

Thu, 15 Oct 2026 16:06:00 -0400

Nyxoah SA (Nasdaq: NYXH) announced that complete 12-month results from the ACCCESS U.S. pivotal study were presented at the International Surgical Sleep Society annual meeting in Los Angeles on October 15, 2026.

The study evaluated the Genio bilateral hypoglossal neurostimulation system in adults with moderate to severe obstructive sleep apnea (OSA) and Complete Concentric Collapse (CCC) of the soft palate. CCC patients are currently contraindicated for unilateral hypoglossal nerve stimulation in the United States, and no commercially available neurostimulation option exists for this population domestically.

Both co-primary efficacy endpoints were met. The Apnea-Hypopnea Index (AHI) responder rate reached 77.2% and the Oxygen

Nyxoah reports 12-month ACCCESS study data at ISSS meeting

Thu, 15 Oct 2026 16:06:00 -0400

Both co-primary efficacy endpoints were met. The Apnea-Hypopnea Index (AHI) responder rate reached 77.2% and the Oxygen

Full 12-Month Data from the ACCCESS U.S. Pivotal Study in Complete Concentric Collapse Patients Presented at ISSS 2026

Thu, 15 Oct 2026 16:05:00 -0400

Full 12-Month Data from the ACCCESS U.S. Pivotal Study in Complete Concentric Collapse Patients Presented at ISSS 2026

Genio® bilateral stimulation delivered a 74.3% median reduction in AHI at 12 months, with no device- or procedure-related serious adverse events

PMA supplement submitted to the FDA to expand Genio’s indication to CCC patients

Mont-Saint-Guibert, Belgium – October 15, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced

Full 12-Month Data from the ACCCESS U.S. Pivotal Study in Complete Concentric Collapse Patients Presented at ISSS 2026

Thu, 15 Oct 2026 16:05:00 -0400

Full 12-Month Data from the ACCCESS U.S. Pivotal Study in Complete Concentric Collapse Patients Presented at ISSS 2026

Genio® bilateral stimulation delivered a 74.3% median reduction in AHI at 12 months, with no device- or procedure-related serious adverse events

PMA supplement submitted to the FDA to expand Genio’s indication to CCC patients

Form 6-K Nyxoah SA For: Sep 29

Tue, 29 Sep 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260929/27122434.html

Nyxoah Appoints Liam Kelly as Chief Executive Officer

Mon, 28 Sep 2026 16:30:00 -0400

REGULATED INFORMATION
INSIDE INFORMATION

Nyxoah Appoints Liam Kelly as Chief Executive Officer

Further strengthening the Company’s strategic U.S. presence and focus

Mont-Saint-Guibert, Belgium – September 28, 2026, 10:30 pm CET / 4:30 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the appointment of Liam Kelly as Chief Executive Officer, effective October 1, 2026, succeeding Olivier Taelman.

The appointment reflects Nyxoah’s continued evolution into a U.S.-focused commercial organization following FDA

Nyxoah Appoints Liam Kelly as Chief Executive Officer

Mon, 28 Sep 2026 16:30:00 -0400

REGULATED INFORMATION
INSIDE INFORMATION

Nyxoah Appoints Liam Kelly as Chief Executive Officer

Further strengthening the Company’s strategic U.S. presence and focus

The appointment reflects Nyxoah’s continued evolution into a U.S.-focused commercial organization following FDA

Nyxoah Appoints Liam Kelly as Chief Executive Officer

Mon, 28 Sep 2026 16:30:00 -0400

REGULATED INFORMATION
INSIDE INFORMATION

Nyxoah Appoints Liam Kelly as Chief Executive Officer

Further strengthening the Company’s strategic U.S. presence and focus

The appointment reflects Nyxoah’s continued evolution into a U.S.-focused commercial organization following FDA

Nyxoah Appoints Liam Kelly as Chief Executive Officer

Mon, 28 Sep 2026 16:30:00 -0400

REGULATED INFORMATION
INSIDE INFORMATION

Nyxoah Appoints Liam Kelly as Chief Executive Officer

Further strengthening the Company’s strategic U.S. presence and focus

The appointment reflects Nyxoah’s continued evolution into a U.S.-focused commercial organization following FDA

Nyxoah Appoints Liam Kelly as Chief Executive Officer

Mon, 28 Sep 2026 16:30:00 -0400

REGULATED INFORMATION
INSIDE INFORMATION

Nyxoah Appoints Liam Kelly as Chief Executive Officer

Further strengthening the Company’s strategic U.S. presence and focus

The appointment reflects Nyxoah’s continued evolution into a U.S.-focused commercial organization following FDA

Nyxoah Appoints Liam Kelly as Chief Executive Officer

Mon, 28 Sep 2026 16:30:00 -0400

REGULATED INFORMATION
INSIDE INFORMATION

Nyxoah Appoints Liam Kelly as Chief Executive Officer

Further strengthening the Company’s strategic U.S. presence and focus

The appointment reflects Nyxoah’s continued evolution into a U.S.-focused commercial organization following FDA

Form 6-K Nyxoah SA For: Sep 22

Tue, 22 Sep 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260922/27091069.html

CVRx names John Landry as its new chief financial officer

Mon, 21 Sep 2026 16:07:36 -0400

CVRx, Inc. (NASDAQ: CVRX) announced the appointment of John Landry as Chief Financial Officer, succeeding Jared Oasheim, who previously announced his resignation. According to a press release, Landry will join the Minneapolis-based medical device company on October 12, 2026, and will assume the CFO role the day after CVRx files its Form 10-Q for the quarter ending September 30, 2026. Oasheim will remain with the company during a transition period consistent with his previously disclosed transition agreement.

Landry brings more than two decades of financial leadership experience in the medical device industry. He currently serves as CFO of Nyxoah SA (Euronext

CVRx names John Landry as its new chief financial officer

Mon, 21 Sep 2026 16:07:36 -0400

Landry brings more than two decades of financial leadership experience in the medical device industry. He currently serves as CFO of Nyxoah SA (Euronext

CVRx Appoints John Landry as Chief Financial Officer

Mon, 21 Sep 2026 16:07:00 -0400

MINNEAPOLIS, Sept. 21, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that John Landry has been appointed Chief Financial Officer, succeeding Jared Oasheim, whose resignation was previously announced. Mr. Landry will join the Company on October 12, 2026, and assume the CFO role on the day after the Company files its Form 10-Q for the quarter ending September 30, 2026. Mr. Oasheim will remain with the Company for a transition period consistent with his previously disclosed

CVRx Appoints John Landry as Chief Financial Officer

Mon, 21 Sep 2026 16:07:00 -0400

CVRx Appoints John Landry as Chief Financial Officer

Mon, 21 Sep 2026 16:07:00 -0400

CVRx Appoints John Landry as Chief Financial Officer

Mon, 21 Sep 2026 16:07:00 -0400

Nyxoah CFO steps down; interim replacement named

Mon, 21 Sep 2026 16:01:14 -0400

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announced that John Landry, its Chief Financial Officer, will step down effective October 2, 2026, to pursue another professional opportunity.

Loïc Moreau, the company's President International and former CFO, will serve as interim CFO upon Landry's departure while Nyxoah conducts a search for a permanent successor.

Moreau joined Nyxoah in 2022 as CFO before transitioning to President International in 2024. He previously held senior roles at GSK, including positions in M&A/Corporate Development and as Country CFO across multiple geographies, and began his career in external audit at EY and corporate finance at PwC.

"We are fortunate to have

Nyxoah Announces Chief Financial Officer Transition

Mon, 21 Sep 2026 16:01:00 -0400

REGULATED INFORMATION
INSIDE INFORMATION

Nyxoah Announces Chief Financial Officer Transition

Loïc Moreau, Nyxoah’s President International and former CFO, to serve as interim CFO

Company reaffirms full year 2026 financial guidance

Mont-Saint-Guibert, Belgium – September 21, 2026, 22:01h CET / 4:01h ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that John Landry, Chief Financial Officer, will step down from his role effective October 2, 2026 to pursue another professional opportunity. Loïc Moreau,

Nyxoah Announces Chief Financial Officer Transition

Mon, 21 Sep 2026 16:01:00 -0400

REGULATED INFORMATION
INSIDE INFORMATION

Nyxoah Announces Chief Financial Officer Transition

Loïc Moreau, Nyxoah’s President International and former CFO, to serve as interim CFO

Company reaffirms full year 2026 financial guidance

Cantor Fitzgerald Reiterates Overweight Rating on Nyxoah SA (NYXH)

Tue, 15 Sep 2026 09:30:39 -0400

Cantor Fitzgerald analyst Sarah James reiterated an Overweight rating and $6.00 price target on Nyxoah SA (NASDAQ: NYXH).

The analyst commented, "NYXH's message continues to shift from clinical proof-of-concept to disciplined commercial execution in the U.S. Genio launch, reinforced days earlier when ACCCESS hit its 12-month co-primary endpoints (77.2% AHI responder rate, zero device-related SAEs), keeping the PMA submission on track for late-3Q26/early-4Q26 and CCC label expansion for late-1Q27/ early-2Q27. Management struck a confident tone on sales force scaling, surgeon adoption, and the path to profitability."

For an analyst ratings summary and ratings history on Nyxoah SA click here. For more